Drug Development
Roche to discontinue codevelopment of daclizumab
Published in Biotech Business Week, December 25th, 2006
Roche made this decision subsequent to a periodic internal review of its development programs. This decision follows another decision by Roche earlier this year to discontinue its involvement in the co-development of daclizumab for the treatment of asthma. The codevelopment agreement between PDL and Roche will formally terminate in May 2007.
As a result, PDL will hold exclusive development and commercial rights to daclizumab for transplant maintenance, which...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
More Articles from Biotech Business Week
- Market Analysis
Albany, NY hospitals blame Medicare/Medicaid reimbursements in struggle for profitability - Market Analysis
Mass spectrometry growing as tool for tailored drugs and biomarker ID, market analysis shows - Market Analysis
Report by Millennium Research shows fetal video continues to grow despite U.S. FDA objection - Market Analysis
Report offers coverage of clinical applications of first- and next-generation molecular diagnostics - Market Analysis
Targeted cancer therapies expand oncology market by raising treatment age limit, report finds - Anti-Infectives
Research from Duke University, Department of Medicine provides new data on anti-infectives - More from this issue of Biotech Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
